急性和亚急性尾炎的皮质类固醇治疗 - 一个案例系列
Yeng F Her1, Ryan T McWilliams2, Erik A Ovrom3
1Department of Anesthesiology and Perioperative Medicine, Mayo Clinic Hospital, Rochester, MN, USA.
International medical case reports journal
|April 1, 2024
概括
疼痛手术后的急性arachnoiditis可以有效地用皮质类固醇治疗. 早期诊断和类固醇干预导致三名患者的良好结果,提供了新的治疗见解.
科学领域:
- 神经外科 神经外科
- 疼痛医学 医学 疼痛医学
- 炎症性疾病 炎症性疾病
背景情况:
- 甲状腺炎带来了重大的治疗挑战,往往导致患者对保守疗法的丧.
- 手术干预可能只能为arachnoiditis提供暂时的疼痛缓解.
- 疼痛手术后的急性arachnoiditis是一个公认的但具有挑战性的并发症.
研究的目的:
- 在不同的疼痛干预措施后,提出三例急性arachnoiditis的病例.
- 为了评估皮质类固醇治疗程序诱导的尾炎的疗效.
- 为管理疼痛后的急性和亚急性尾炎提供见解.
主要方法:
- 三名被诊断患有急性尾炎的患者的病例系列介绍.
- 干预措施包括 epidural 血液贴片,植入式药物输送系统 (IDDS) 放置和 epidural 类固醇注射.
- 治疗涉及皮质类固醇 (口服和/或静脉注射),在手术后10天内开始.
主要成果:
- 这三名患者都接受了针对急性arachnoiditis的皮质类固醇治疗.
- 两名患者接受了口服类固醇治疗;一名患者接受了口服和静脉注射类固醇.
- 所有患者在完成类固醇治疗后都取得了良好的结果.
结论:
- 皮质类固醇治疗在治疗疼痛干预后的急性arachnoiditis中似乎是有效的.
- 早期诊断和及时的类固醇管理对于积极的结果至关重要.
- 这一案例系列表明了与程序相关的尾炎的潜在治疗途径.
相关概念视频
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
116
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
116
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
243
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
243
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
162
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
162
01:26COPD: Management Using Bronchodilators and Corticosteroids
202
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
202
01:29Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127